For UK pharmaceutical and life sciences leaders
Your reps and events are reaching fewer HCPs than they did three years ago
Post-Covid, HCP attention has migrated to digital channels, peer networks, and on-demand medical education. Campaigns built around the old model keep losing reach and return with each cycle.
Two minutes. Solva follows up with specific HCP engagement options.
- Declining attendance at traditional medical conferences and events
- Low engagement rates on emails and content not tailored to specific HCP interests
- Sales representatives struggling to secure meetings with key prescribers
- Increased reliance on online medical communities and digital opinion leaders for information
- Inefficient allocation of marketing and sales resources
- Difficulty in reaching key opinion leaders (KOLs) and high-value prescribers
- Increased cost per interaction with HCPs through traditional channels
- Reduced return on investment (ROI) from marketing budgets
- Delayed dissemination of critical medical information to HCPs
- Suboptimal prescribing practices due to lack of up-to-date product knowledge
- Perception of the pharmaceutical company as outdated or slow to adapt
- Erosion of trust with HCPs who prefer modern, convenient engagement methods
No verified UK data available
Source: No verified UK data available
Frequently asked questions
Why does this problem persist?
HCP engagement has shifted dramatically post-Covid. Digital channels, peer-to-peer networks, and online medical education have replaced many traditional rep-based interactions. Companies that haven't adapted are spending more to reach fewer prescribers.
What is the cost of leaving it unaddressed?
No verified UK data available
This is exactly what I do with UK private practices. Answer the few questions above and I'll come back personally with where to start. Paul.